HexemBio Secured $15.5 Million for Stem Cell Therapy
The company aims to start clinical trials by 2027 using a synthetic platform that rejuvenates hematopoietic stem cells.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust that medical research companies prioritize patient health outcomes over potential profit margins?
HexemBio has secured $15.5 million in a new investment round led by Draper Associates to advance its research-stage cellular therapy. The company uses a synthetic environment to rejuvenate hematopoietic stem cells, which are cells that give rise to all blood cell types, for potential use in bone marrow transplants.
Why it matters
By targeting bone marrow transplants for blood cancer, HexemBio is attempting to establish the clinical feasibility of its cellular rejuvenation platform before pursuing broader applications in systemic aging. This milestone marks a critical transition from lab-based research toward human safety assessments.
HexemBio raised $15.5 million in its latest round, following a $10.4 million seed round earlier this year. Korea Investment Partners contributed $2 million to the recent $15.5 million total.
The players
HexemBio
A biotech startup established in 2024 that focuses on regenerative medicine using a synthetic platform to revitalize stem cells.
Draper Associates
A venture capital firm known for early-stage investments in technology and life sciences that led the recent funding round.
Korea Investment Partners
A Seoul-based venture capital firm with an extensive portfolio in global biotech and healthcare technology.
The details
The company uses a proprietary platform called the Synthetic Human Yolk Sac, which aims to recreate the cellular and molecular signals present during early human development. The therapy works by extracting a patient's own hematopoietic stem cells—the precursor cells that produce blood and immune cells—and exposing them to this synthetic environment. The rejuvenated cells are then reinfused into the patient to restore function, a process intended to address health conditions starting with bone marrow transplants.
Timeline
July 2025: HexemBio received FDA Orphan Drug Designation.
January 2026: The company completed a pre-Investigational New Drug meeting.
March 2026: HexemBio raised $10.4 million in seed funding.
September 2026: The company secured $15.5 million in new investment.
2027: Clinical trials for bone marrow transplant patients are scheduled to begin.
The Tech Race
HexemBio is operating within a crowded field of regenerative medicine firms attempting to reverse cellular decline. Following its July 2025 FDA Orphan Drug Designation, the company is now positioning itself to validate its proprietary synthetic Yolk Sac platform against traditional ex vivo cell expansion methods.
This development is currently limited to research-stage efforts and will not impact patient treatment or clinical workflows until successful human trial results are published. The technology remains inaccessible to the public as it undergoes pre-clinical validation and regulatory preparations.
The takeaway
HexemBio is transitioning its synthetic Yolk Sac platform from a theoretical model to a regulated clinical therapy. Stakeholders should monitor the company's progress toward the 2027 trial start date, which will provide the first significant data on its rejuvenation technology in human subjects.
What happens next
HexemBio is scheduled to initiate its first clinical trials for bone marrow transplant patients in 2027.
Further reading
Explore the latest developments in cellular rejuvenation and therapeutic innovation at Biotech.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust that medical research companies prioritize patient health outcomes over potential profit margins?
